A Pilot Study to Test the Feasibility of the Combination of Gemcitabine and CT-011 in the Treatment of Resected Pancreatic Cancer.

Trial Profile

A Pilot Study to Test the Feasibility of the Combination of Gemcitabine and CT-011 in the Treatment of Resected Pancreatic Cancer.

Suspended
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Pidilizumab (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jun 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2018.
    • 15 Jul 2015 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018 as per ClinicalTrials.gov record.
    • 15 Jul 2015 Status changed from recruiting to suspended as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top